Trial reportHypertension (Dallas, Tex. : 1979)2019
Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.
Trial report in Hypertension (Dallas, Tex. : 1979), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00751972 (Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Intensive Versus Standard Blood Pressure Control in Type 2 Diabetes: Cardiovascular and Microvascular Outcomes.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Pooled it
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Walking for hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes.Journal of human hypertension · 2023Trial
- Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE.International journal of cardiology · 2022Trial
- Updates in the 2025 AHA/ACC Hypertension Guideline.Current hypertension reports · 2026Review
- Diabetes, stroke severity and hemodynamic cerebral ischemia.Cardiovascular diabetology. Endocrinology reports · 2025Article
- A retrospective multicentre study on the outcomes of the pharmacist-managed Diabetes Medication Therapy Adherence Clinic programme in primary health clinics across Johor, Malaysia.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2025Article
- Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.The lancet. Diabetes & endocrinology · 2022Article
- Application of Mediterranean Diet in Cardiovascular Diseases and Type 2 Diabetes Mellitus: Motivations and Challenges.Nutrients · 2022Review
- Predictive value of visit-to-visit blood pressure variability for cardiovascular events in patients with coronary artery disease with and without diabetes mellitus.Cardiovascular diabetology · 2021Article
- Guideline-Driven Management of Hypertension: An Evidence-Based Update.Circulation research · 2021Review
- Impact of the Stress Status of Employees on the Enterprise Technology Management Cost Through Matter-Element Analysis Under Psychological Health Education.Frontiers in psychology · 2021Article
- Antidiabetic Properties of Curcumin: Insights on New Mechanisms.Advances in experimental medicine and biology · 2021Review
- Intensive blood pressure lowering: a practical review.Clinical hypertension · 2020Review
- Evidence for and Against ACC/AHA 2017 Guideline for Target Systolic Blood Pressure of < 130 mmHg in Persons with Type 2 Diabetes.Current cardiology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 7 countries.
Funding
Abstract
The optimal blood pressure (BP) goal in patients with diabetes mellitus remains controversial. We examined whether benefits and risks of intensified antihypertensive therapy in diabetes mellitus are influenced by either baseline BP or cardiovascular disease (CVD) risk. We studied 10 948 people with diabetes mellitus, at moderate-to-high risk, in the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation). Cox models were used to determine whether baseline BP category or CVD risk modified the outcomes of combination perindopril-indapamide treatment, compared with placebo. During 4.3 years of follow-up, treatment with perindopril-indapamide versus placebo reduced mortality and major vascular (macrovascular or microvascular) events. There was no evidence of differences in these effects, regardless of baseline systolic BP (evaluated down to <120 mm Hg; P for heterogeneity, 0.85), diastolic BP (evaluated down to <70 mm Hg; P=0.49), or whether 10-year CVD risk was ≥20% or <20% ( P=0.08). The effects of randomized treatment on discontinuation of treatment because of cough or hypotension/dizziness were also statistically consistent across subgroups defined by baseline BP and CVD risk (all P ≥0.08). Adults with diabetes mellitus appear to benefit from more intensive BP treatment even at levels of BP and CVD risk that some guidelines do not currently recommend for intervention. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT00751972.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.